Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Survival and time interval from surgery to the start of chemotherapy for patients with stage II and III colon cancer.

Ganenko D, Dulskas A, Kuliešius Ž, Baltruškevičienė E, Urbonas V, Stratilatovas E.

Acta Med Litu. 2018;25(3):161-165. doi: 10.6001/actamedica.v25i3.3863.

2.

Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.

Baltruskeviciene E, Schveigert D, Stankevicius V, Mickys U, Zvirblis T, Bublevic J, Suziedelis K, Aleknavicius E.

BMC Cancer. 2017 Sep 1;17(1):607. doi: 10.1186/s12885-017-3575-z.

3.

Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment.

Baltruskeviciene E, Kazbariene B, Aleknavicius E, Krikstaponiene A, Venceviciene L, Suziedelis K, Stratilatovas E, Didziapetriene J.

Tumori. 2018 Oct;104(5):375-380. doi: 10.5301/tj.5000674. Epub 2018 May 8.

PMID:
28777429
4.

Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment.

Baltruskeviciene E, Kazbariene B, Aleknavicius E, Krikstaponiene A, Suziedelis K, Stratilatovas E, Didziapetriene J.

Ann Oncol. 2017 Jun;28 Suppl 3:iii97. doi: 10.1093/annonc/mdx261.276. No abstract available.

5.

Asymptomatic primary tumour in incurable metastatic colorectal cancer: is there a role for surgical resection prior to systematic therapy or not?

Samalavicius NE, Dulskas A, Baltruskeviciene E, Smailyte G, Skuciene M, Mikelenaite R, Venslovaite R, Aleknavicius E, Samalavicius A, Lunevicius R.

Wideochir Inne Tech Maloinwazyjne. 2016;11(4):274-282. doi: 10.5114/wiitm.2016.64981. Epub 2016 Dec 31.

6.

Glutathione and glutathione S-transferase levels in patients with liver metastases of colorectal cancer and other hepatic disorders.

Baltruskeviciene E, Kazbariene B, Badaras R, Bagdonaitė L, Krikštaponienė A, Zdanavičius L, Aleknavicius E, Didziapetrienė J.

Turk J Gastroenterol. 2016 Jul;27(4):336-41. doi: 10.5152/tjg.2016.15457.

7.

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.

Baltruškevičienė E, Mickys U, Žvirblis T, Stulpinas R, Pipirienė Želvienė T, Aleknavičius E.

Acta Med Litu. 2016;23(1):24-34. doi: 10.6001/actamedica.v23i1.3267.

8.

Rhabdoid carcinoma of the rectum.

Samalavicius NE, Stulpinas R, Gasilionis V, Baltruskeviciene E, Aleknavicius E, Mickys U.

Ann Coloproctol. 2013 Dec;29(6):252-5. doi: 10.3393/ac.2013.29.6.252. Epub 2013 Dec 31.

Supplemental Content

Loading ...
Support Center